CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Celldex Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$29.67+2.14 (+7.77%)
Close on Oct 19, 2026
- Market cap
- $2.31B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$2.84 (+10.59%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Celldex Therapeutics, Inc. saw revenue fall 97.3% to $158.00K over the twelve months to Jun 30, 2026. Free cash flow was -$242.11M.
Revenue
$158.00K
-97.3% vs. a year earlier
Operating income
-$325.83M
TTM Q2 2026
Free cash flow
-$242.11M
TTM Q2 2026
EPS, diluted
-$3.90
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.31B
- P/E ratio
- –
- Price to sales
- 14617.17
- Price to book
- 3.23
- Dividend yield
- –
- Free cash flow yield
- -10.48%
Fundamentals
- Revenue
- $158.00K
- Net income
- -$300.55M
- EPS, diluted
- -$3.90
- Free cash flow
- -$242.11M
- Book value per share
- $9.18
- Diluted shares
- 78M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$158.00K-97.3% YoY
Gross profit
–
Operating income
-$325.83M
Net income
-$300.55M
EPS, diluted
–
Free cash flow
-$242.11M
Reported periodTrailing twelve months